AVR

Anteris Technologies announced that it will present first 30-day clinical and hemodynamic outcomes for its medium-size DurAVR Transcatheter Heart Valve at the TCT 2026 conference in San Diego. The presentation will showcase results from the ongoing EMBARK study, which has treated over 130 patients with the DurAVR THV since 2021. The company will also feature a live case demonstration of the biomimetic valve technology.

Anteris Technologies announced it has received full regulatory clearance from Germany's BfArM to initiate the PARADIGM Trial for its DurAVR Transcatheter Heart Valve in patients with severe aortic stenosis. The clearance enables patient recruitment at leading German centers and strengthens the trial's European expansion, as Germany represents Europe's largest TAVR market with extensive clinical infrastructure.